Incontinence News and Research

Latest Incontinence News and Research

25% of adults quit their overactive bladder medication: Study

Study of 5,392 adults found that a quarter had quit their overactive bladder medication, with nine out of ten saying it didn't work as expected or they couldn't tolerate it. A follow-up study found that being a current smoker raised the risk of quitting by 80%, having an enlarged prostate by 74% and believing that bladder medication caused side effects by 111%.

13 May 2010

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

Nymox Pharmaceutical Corporation provided an update today on the Company's Phase 3 program for NX-1207, Nymox's investigational drug for benign prostatic hyperplasia. The most recent Safety Monitoring Committee meeting of April 30, 2010 for the Phase 3 U.S. pivotal trials of NX-1207 indicated no significant safety concerns for the trials to date.

12 May 2010

MediciNova announces $15 million senior secured term loan with Oxford Finance

MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today announced that it has entered into a $15 million senior secured term loan with Oxford Finance Corporation.

11 May 2010

PTNS performed using Urgent PC Neuromodulation System to receive category 1 CPT reimbursement code

Uroplasty, Inc., a medical device company that develops, manufactures and markets innovative proprietary products to treat voiding dysfunctions, announced today that it has been informed that percutaneous tibial nerve stimulation (PTNS), the procedure performed using the Uroplasty Urgent PC Neuromodulation System, will receive a category 1 CPT reimbursement code. This is expected to occur when those codes are published by the Centers for Medicare and Medicaid Services, which is expected in October 2010.

6 May 2010

Research analyzes clinical connection of NPH to AD

Normal Pressure Hydrocephalus is a neurological condition which typically affects adults ages 55 and older. This condition was first described in the 1960s as a triad of gait disturbance, dementia, and bladder incontinence. The ventricles of the brain appear enlarged although the cerebrospinal fluid pressure remains normal.

5 May 2010

Pelvic Floor Institute launched to enhance physician knowledge on reconstruction procedures, techniques

Boston Scientific Corporation today announced the launch of the Pelvic Floor Institute -- a unique training forum and online resource designed to enhance physician knowledge and awareness of pelvic floor reconstruction procedures and techniques.

30 Apr 2010

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.

30 Apr 2010

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

Kathleen Keef, Ph.D., professor of physiology and cell biology at the University of Nevada School of Medicine, has been awarded a four-year, $1.2 million grant from the National Institute of Health to study the control of motility in the internal anal sphincter.

22 Apr 2010

Budget impact of traditional fecal management methods to be presented at SAWC/WHS 2010

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced new study results that demonstrate hospitals could realize substantial savings by substituting Flexi-Seal FMS for traditional fecal management methods.

19 Apr 2010

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Treatment options for idiopathic OAB patients not adequately managed by anticholinergic therapy are limited; either highly invasive, expensive or of limited efficacy. BOTOX® (onabotulinumtoxinA) may provide a minimally invasive effective treatment. Professor Chris Chapple and his group conducted the first large, double-blind, placebo-controlled, dose ranging study to systematically asses the benefit/risk balance of the use of BOTOX® in IOAB across a wide range of doses.

19 Apr 2010

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

A new study of almost 700 patients from The Mount Sinai Medical Center shows that prostate cancer patients who had robotically assisted prostatectomy enjoyed significant benefits over patients who had a traditional open radical prostatectomy, including decreased surgical and recovery time, less blood loss during surgery and significantly shorter hospital stays.

16 Apr 2010

Trans-urethral prostate hyperthermia treatment offers 100% response rate

According the Dr. Friedrich Douwes, Medical Director of St. George Hospital in Bad Aibling, Germany, president of the German Oncological Society and the author of several hundred scientific articles and books, trans-urethral prostate hyperthermia has a 100% initial response rate.

16 Apr 2010

Contura submits PMA for Aquamid

Contura Inc. has submitted a Premarket Approval Application for Aquamid to the U.S. Food and Drug Administration requesting marketing approval in the U.S. for the aesthetic treatment of moderate to severe facial wrinkles and folds.

16 Apr 2010

NAFC holds free educational webinar for seniors who live with incontinence

The National Association For Continence is holding a free educational webinar, Nocturia: Risk Factors for Falls & Fractures and Nighttime Fall Prevention Strategies, on Tuesday, April 20 at 8 p.m. (EST). This event will benefit seniors who live with incontinence and their caregivers.

13 Apr 2010

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

Oceana Therapeutics and Q-Med AB today announced the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for Solesta® for the treatment of Fecal (or Bowel) Incontinence, a largely unsatisfied medical need afflicting millions of Americans.

12 Apr 2010

PSA test distress, study urges caution

A new study wants men to be informed about risks associated with screening for prostate cancer. The research has brought out that the prostate cancer tests can cause significant psychological distress to the men undergoing the screening. 330 men were studied by the University of Bristol as they underwent the tests and after they finished.

9 Apr 2010

ANA recognizes WOC nursing as specialty

Wound, Ostomy and Continence nursing is one of the newest specialties recognized by the American Nurses Association. The Wound, Ostomy & Continence Nurses Society was recently notified of the ANA's decision.

8 Apr 2010

Dutasteride may help reduce risk of developing prostate cancer, say researchers

A drug already used to shrink benign, enlarged prostates could also help to reduce the risk of developing prostate cancer, according to researchers in the US.

8 Apr 2010

New study to compare Botox against oral medications for urge incontinence in women

A new study is underway at Loyola University Health System to compare botulinum toxin A or Botox® versus common oral medications for urge incontinence in women. Urge incontinence is urinary incontinence with a strong or sudden need to urinate. Millions of women suffer in silence each day from this condition.

6 Apr 2010

Clinical utility and pharmacological action of MN-166 in treatment of MS

MediciNova, Inc, a biopharmaceutical company publicly traded on the Nasdaq Global Market and the Hercules Market of the Osaka Securities Exchange, today reported that this week's issue of Neurology includes two articles related to the potential clinical utility and unique pharmacological action of MN-166 in treating multiple sclerosis (MS).

3 Apr 2010

Incontinence News and Research

Latest Incontinence News and Research

25% of adults quit their overactive bladder medication: Study

Update on Nymox Pharmaceutical's Phase 3 program for NX-1207

MediciNova announces $15 million senior secured term loan with Oxford Finance

PTNS performed using Urgent PC Neuromodulation System to receive category 1 CPT reimbursement code

Research analyzes clinical connection of NPH to AD

Pelvic Floor Institute launched to enhance physician knowledge on reconstruction procedures, techniques

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

University of Nevada professor awarded NIH RO1 grant for study of control of motility in internal anal sphincter

Budget impact of traditional fecal management methods to be presented at SAWC/WHS 2010

Results from Phase 2 study of BOTOX in IOAB patients presented at Anniversary EAU Congress

Prostate cancer patients having robotic prostatectomy enjoy significant benefits: Study

Trans-urethral prostate hyperthermia treatment offers 100% response rate

Contura submits PMA for Aquamid

NAFC holds free educational webinar for seniors who live with incontinence

Oceana Therapeutics, Q-Med submit Solesta PMA application for treatment of fecal incontinence

PSA test distress, study urges caution

ANA recognizes WOC nursing as specialty

Dutasteride may help reduce risk of developing prostate cancer, say researchers

New study to compare Botox against oral medications for urge incontinence in women

Clinical utility and pharmacological action of MN-166 in treatment of MS

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Incontinence News and Research

Latest Incontinence News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in